MLEC vs DBVT vs ALKS vs RKDA vs PGEN

For growth investors, Moolec Science S.

A. (MLEC) is the stronger pick with 58. 3% revenue growth year-over-year, versus -36. 9% for Precigen, Inc. (PGEN). Alkermes plc (ALKS) offers the better valuation at 24. 5x trailing P/E, making it the more compelling value choice. Analysts rate DBV Technologies S. A. (DBVT) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Alkermes plc (ALKS) delivered a total return of +61.

7%, compared to -98. 9% for Arcadia Biosciences, Inc. (RKDA). Over 10 years, the gap is even starker: MLEC returned -9. 3% versus RKDA's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Moolec Science S.

A. (MLEC) is the lower-risk stock at 0. 76β versus Precigen, Inc. 's 1. 43β — meaning PGEN is approximately 87% more volatile than MLEC relative to the S&P 500. On balance sheet safety, Alkermes plc (ALKS) carries a lower debt/equity ratio of 4% versus 14% for Precigen, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Moolec Science S.

A. (MLEC) is pulling ahead at 58. 3% versus -36. 9% for Precigen, Inc. (PGEN). On earnings-per-share growth, the picture is similar: Arcadia Biosciences, Inc. grew EPS 66. 9% year-over-year, compared to -89. 8% for Moolec Science S. A.. Over a 3-year CAGR, ALKS leads at 9. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Alkermes plc (ALKS) is the more profitable company, earning 16.

4% net margin versus -32. 2% for Precigen, Inc. — meaning it keeps 16. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ALKS leads at 17. 2% versus -34. 4% for PGEN. At the gross margin level — before operating expenses — ALKS leads at 86. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Moolec Science S.

A. (MLEC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 76)). Both have compounded well over 10 years (MLEC: -9. 3%, PGEN: -84. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MLEC (Healthcare) and DBVT (Healthcare) and ALKS (Healthcare) and RKDA (Basic Materials) and PGEN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MLEC is a small-cap high-growth stock; DBVT is a mega-cap quality compounder stock; ALKS is a small-cap quality compounder stock; RKDA is a small-cap quality compounder stock; PGEN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.